Tradjenta insulin tablets receive FDA approval
Boehringer Ingelheim Pharmaceuticals clinical development and medical affairs senior vice president John Smith said with FDA decision, Tradjenta can be an effective add-on therapy with a demonstrated safety
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.